Učitavanje...
Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report
Lenalidomide has been developed as the derivative of thalidomide that has fewer side effects. We herein report a rare case of castration‐resistant prostate cancer successfully maintained using lenalidomide for multiple myeloma.
Spremljeno u:
| Izdano u: | Clin Case Rep |
|---|---|
| Glavni autori: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5799614/ https://ncbi.nlm.nih.gov/pubmed/29445483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1328 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|